Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises O2 in connection with its application for listing on NASDAQ OMX Stockholm
Mandate

Vinge advises O2 in connection with its application for listing on NASDAQ OMX Stockholm

March 09, 2010

Vinge is advising the wind power company OM Vind AB in connection with the company’s application for listing on NASDAQ OMX Stockholm. The expected first day of trading is 22 March 2010. A new issue of not less than MSEK 950 and not more than MSEK 1,150 will be performed in conjunction with the listing. SEB Enskilda and Swedbank Markets are Joint Lead Managers and Book Runners in the offering. Vinge is also advising on the restructuring of O2’s legal structure which will take place prior to O2’s shares being admitted to trading. Vinge has also advised O2 in connection with negotiation of loan agreements in the amount of approximately SEK 2.4 billion with a Nordic bank consortium consisting of DnB Nor, SEB and Swedbank.

Vinge’s team primarily consists of Lena Almefelt, Petter Alberts, Fredrik Stjernström, Helena Backlund, Christian Johansson, Johan Cederblad, Kimmie Johansson and Andreas Wirén. As regards the loan financing aspect of the transaction, Vinge’s team primarily consists of Mikael Ståhl, Christian Johansson and Ulrica Åkesson.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025